GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial.

@article{Elias2005GMCSFAI,
  title={GM-CSF and IL-2 combination as adjuvant therapy in cutaneous melanoma: early results of a phase II clinical trial.},
  author={Elias George Elias and John Louis Zapas and Sandra L Beam and Sally D Brown},
  journal={Oncology},
  year={2005},
  volume={19 4 Suppl 2},
  pages={15-8}
}
Cytokines have been used in the treatment of patients with cutaneous melanoma. Granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim [Leukine]) leads to dendritic cell/macrophage priming and activation, and also increases interleukin-2 (IL-2) receptor expression on T. lymphocytes. IL-2 creates lymphokine-activated killer cells and tumor-infiltrating lymphocyte cells. In this open-label, single-arm study of 16 high-risk patients, we combined these two agents to take advantage of… CONTINUE READING